Kinoxis Therapeutics raises $6.75M in equity and $2.5M grant to advance dementia agitation treatments through clinical trials, with results expected in 2027.
Amount Raised
A$6.75 Million
Round Type
Seed
MelbourneBiotechnologyHealth CareTherapeuticsInvestors
Description
Kinoxis Therapeutics, a dementia biotech company, has secured $6.75 million in equity funding led by Main Sequence Ventures, along with a $2.5 million government grant from Australia's Medical Research Future Fund. The total $9.25 million will fund clinical trials for drugs targeting agitation and pain associated with dementia. The company's lead candidate, KNX100, is in Phase 2 trials with initial results expected in mid-2027.
Who to call at Kinoxis Therapeutics, and when
A new round usually means Kinoxis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kinoxis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kinoxis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kinoxis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kinoxis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Kinoxis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.